BRPI0920552A2 - nanosistemas poliméricos auto-organizáveis multifuncionais - Google Patents

nanosistemas poliméricos auto-organizáveis multifuncionais

Info

Publication number
BRPI0920552A2
BRPI0920552A2 BRPI0920552A BRPI0920552A BRPI0920552A2 BR PI0920552 A2 BRPI0920552 A2 BR PI0920552A2 BR PI0920552 A BRPI0920552 A BR PI0920552A BR PI0920552 A BRPI0920552 A BR PI0920552A BR PI0920552 A2 BRPI0920552 A2 BR PI0920552A2
Authority
BR
Brazil
Prior art keywords
organizing
multifunctional self
nanosystems
polymeric
polymeric nanosystems
Prior art date
Application number
BRPI0920552A
Other languages
English (en)
Inventor
K Iyer Arun
M Amiji Mansoor
Original Assignee
Univ Northeastern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northeastern filed Critical Univ Northeastern
Publication of BRPI0920552A2 publication Critical patent/BRPI0920552A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
BRPI0920552A 2008-10-09 2009-10-09 nanosistemas poliméricos auto-organizáveis multifuncionais BRPI0920552A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10405608P 2008-10-09 2008-10-09
US24635509P 2009-09-28 2009-09-28
PCT/US2009/060175 WO2010042823A1 (en) 2008-10-09 2009-10-09 Multifunctional self-assembling polymeric nanosystems

Publications (1)

Publication Number Publication Date
BRPI0920552A2 true BRPI0920552A2 (pt) 2019-09-24

Family

ID=42100975

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920552A BRPI0920552A2 (pt) 2008-10-09 2009-10-09 nanosistemas poliméricos auto-organizáveis multifuncionais

Country Status (7)

Country Link
US (1) US9173840B2 (pt)
EP (1) EP2352490A4 (pt)
JP (1) JP2012505243A (pt)
AU (1) AU2009302217A1 (pt)
BR (1) BRPI0920552A2 (pt)
CA (1) CA2740125A1 (pt)
WO (1) WO2010042823A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8333962B2 (en) * 2009-08-27 2012-12-18 National Health Research Institutes Controlled release multidrug formulations for spinal cord injury
CN101721714B (zh) * 2009-12-18 2011-12-07 重庆莱美药业股份有限公司 实体瘤被动靶向性抗癌前药及其制备方法
US9918656B2 (en) * 2010-06-25 2018-03-20 Massachusetts Institute Of Technology Implantable magnetic relaxation sensors and methods of measuring a sensor's cumulative exposure to a biomarker
WO2012017307A1 (en) * 2010-08-05 2012-02-09 Council Of Scientific & Industrial Research A process for the removal of polymer thermosets from a substrate
EP2645991B1 (en) 2010-12-02 2020-02-12 GreenMark Biomedical Inc. Aptamer bioconjugate drug delivery device
US20140037748A1 (en) * 2011-04-15 2014-02-06 The Regents Of The University Of California Redox responsive polymeric nanocapsules for protein delivery
WO2013033513A1 (en) 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
US9872870B2 (en) 2011-11-04 2018-01-23 University Of Notre Dame Du Lac Multifunctional micellar nanoparticle-based drug and targeting agent system
KR101722948B1 (ko) * 2012-01-05 2017-04-04 (주)바이오니아 리간드가 결합된 이중나선 올리고 ｒｎａ 구조체 및 그 제조방법
WO2013089522A1 (ko) * 2011-12-15 2013-06-20 (주)바이오니아 신규한 올리고뉴클레오티드 접합체 및 그 용도
JP6356614B2 (ja) 2012-02-17 2018-07-11 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド 薬剤のミトコンドリア輸送のためのナノ粒子
US20130261444A1 (en) * 2012-03-28 2013-10-03 The Uab Research Foundation Photothermal nanostructures in tumor therapy
JP2015519312A (ja) * 2012-04-19 2015-07-09 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 高度分岐α−Ｄ−グルカン
EP2841056A4 (en) * 2012-04-23 2015-09-16 Massachusetts Inst Technology STABLE LAYER COATED PARTICLES
EP2866814A4 (en) * 2012-07-02 2015-11-25 Univ Northeastern BIODEGRADABLE POLYMER BUFFER
US20170136123A1 (en) * 2013-01-10 2017-05-18 Amrita Vishwa Vidyapeetham Stannous doped micro and nano particles for augmented radiofrequency ablation
EP2950785A4 (en) 2013-02-04 2016-09-21 Univ Notre Dame Du Lac NANOPARTICLE-drug delivery systems
BR112016000160B1 (pt) 2013-07-05 2021-06-08 Bioneer Corporation estrutura de oligonucleotídeo tipo nanopartícula melhorada tendo alta eficiência e método para a preparação da mesma
CN105705639A (zh) 2013-07-05 2016-06-22 柏业公司 登革病毒相关的基因特异性siRNA、包含该siRNA的双链寡RNA分子、和包含它们的用于抑制登革病毒复制的组合物
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US20170173005A1 (en) 2014-03-27 2017-06-22 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016134002A1 (en) * 2015-02-18 2016-08-25 Memorial Sloan Kettering Cancer Center Compositions and methods for nanoparticle-based drug delivery and imaging
JP6752231B2 (ja) 2015-06-01 2020-09-09 カリフォルニア インスティテュート オブ テクノロジー 抗原を用いて特異的集団に関してｔ細胞をスクリーニングするための組成物および方法
CN105878212B (zh) * 2016-05-27 2018-06-15 四川大学 一种双重细胞微环境敏感的抗肿瘤载药纳米胶囊及制备方法
CN106727423A (zh) * 2016-10-13 2017-05-31 中国药科大学 一种具有双靶向性的氧化还原敏感性的核交联普鲁兰多糖纳米粒及制备方法
WO2018165475A1 (en) 2017-03-08 2018-09-13 California Institute Of Technology Pairing antigen specificity of a t cell with t cell receptor sequences
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
US20210113466A1 (en) * 2017-03-16 2021-04-22 Children's Medical Center Corporation Non-viral, non-cationic nanoparticles and uses thereof
WO2019089567A1 (en) 2017-10-30 2019-05-09 Massachusetts Institute Of Technology Layer-by-layer nanoparticles for cytokine therapy in cancer treatment
WO2019191456A1 (en) 2018-03-28 2019-10-03 Greenmark Biomedical Inc. Phosphate crosslinked starch nanoparticle and dental treatments
CN108562564B (zh) * 2018-03-29 2021-04-02 青岛大学 一种用于菊糖酶活度检测的碳量子点及制备方法和应用
CN109021587B (zh) * 2018-06-07 2020-12-04 宁夏金博乐食品科技有限公司 可食用的明胶基膜及其制备方法
WO2020163630A1 (en) * 2019-02-06 2020-08-13 Singular Genomics Systems, Inc. Compositions and methods for nucleic acid sequencing
WO2021002984A1 (en) 2019-05-30 2021-01-07 Massachusetts Institute Of Technology Peptide nucleic acid functionalized hydrogel microneedles for sampling and detection of interstitial fluid nucleic acids
WO2024191103A1 (ko) * 2023-03-14 2024-09-19 가톨릭대학교 산학협력단 덱사메타손 및 폴리에스터의 고분자 접합체를 포함하는 자기조립 나노입자, 이의 제조방법 및 이를 포함하는 약물전달용 조성물

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939240A (en) 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US4708930A (en) 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4743543A (en) 1985-09-09 1988-05-10 Coulter Corporation Method for enhancing and/or accelerating immunoassay detection of human carcinoma tumor associated antigen in a pathology sample
JPS6319561A (ja) 1986-07-11 1988-01-27 Kyowa Hakko Kogyo Co Ltd 抗ヒト肺癌単クロ−ン性抗体
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4921790A (en) 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
EP0394277B1 (en) 1987-07-15 1998-01-14 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5543508A (en) 1987-12-15 1996-08-06 Gene Shears Pty. Limited Ribozymes
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5053489A (en) 1988-01-29 1991-10-01 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4914021A (en) 1988-03-04 1990-04-03 New England Deaconess Hospital Corporation Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US4921789A (en) 1988-04-20 1990-05-01 New England Deaconess Hospital Corporation Marker for colorectal carcinoma and methods of detecting the same
JPH0734015B2 (ja) 1988-04-25 1995-04-12 和光純薬工業株式会社 微量成分の新規測定法
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
US6083696A (en) 1990-06-11 2000-07-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands exponential enrichment: blended selex
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
PT627940E (pt) 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
ATE187494T1 (de) 1992-12-11 1999-12-15 Dow Chemical Co Multivalente einkettige antikörper
EP0686260B1 (en) 1993-02-05 2003-07-09 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6441158B1 (en) 1997-12-31 2002-08-27 Medical College Of Georgia Research Institute, Inc. Oligomers that bind to ku protein
US6458559B1 (en) 1998-04-22 2002-10-01 Cornell Research Foundation, Inc. Multivalent RNA aptamers and their expression in multicellular organisms
DK1198490T3 (da) 1999-07-14 2006-06-19 Alza Corp Neutral lipopolymer og liposomsammensætninger indeholdende samme
WO2002087541A1 (en) * 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
CA2532228C (en) * 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US7713440B2 (en) * 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
WO2006044660A2 (en) * 2004-10-14 2006-04-27 Vanderbilt University Functionalized solid lipid nanoparticles and methods of making and using same
CA2600085A1 (en) * 2005-03-09 2006-09-14 Toray Industries, Inc. Microparticle and pharmaceutical preparation
US20060222595A1 (en) * 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
MX2007012157A (es) * 2005-04-01 2008-03-14 Intezyne Technologies Llc Micelas polimericas para suministro de farmacos.
US20070048383A1 (en) 2005-08-25 2007-03-01 Helmus Michael N Self-assembled endovascular structures
CA2648099C (en) * 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分

Also Published As

Publication number Publication date
JP2012505243A (ja) 2012-03-01
CA2740125A1 (en) 2010-04-15
WO2010042823A1 (en) 2010-04-15
AU2009302217A1 (en) 2010-04-15
EP2352490A1 (en) 2011-08-10
US20110244048A1 (en) 2011-10-06
EP2352490A4 (en) 2013-11-20
US9173840B2 (en) 2015-11-03

Similar Documents

Publication Publication Date Title
BRPI0920552A2 (pt) nanosistemas poliméricos auto-organizáveis multifuncionais
FI20085999A0 (fi) Kattoelementti
NO2021006I1 (no) Quofenix, delafloksacin
CR10926A (es) Nuevas 2-aminooxazolinas como ligandos taar1
DK2481796T3 (da) Glucoamylasevarianter
EP2272042A4 (en) SMART CAR COMPLETION
PL2331687T3 (pl) Środki przeciwdrobnoustrojowe
EP2396152A4 (en) Router
EP2345301A4 (en) SOFTWARE-DEFINED RADIO
BRPI0918087A2 (pt) construção de edifício
DE112009001577A5 (de) Verstellpumpe
BRPI0919559A2 (pt) baterias
BRPI0905074A2 (pt) Desidratador
FI20086252A0 (fi) Radiovastaanotin
DE102009055010A8 (de) Dachanordnung
FR2951218B1 (fr) Pylone de communication
FI20085902A0 (fi) Porrasrakenne
ES1070015Y (es) Rastrillo multifuncional
ATE521549T1 (de) Verschlusskappe
UA20145S (uk) Ринва
ES1068560Y (es) Parapeto mejorado
ES1065566Y (es) Vallado multifuncional
ITPN20080016U1 (it) Chiosco mobile
ES1071223Y (es) Farola
ES1067637Y (es) Separador balistico

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.